Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer.
- Conditions
- Carcinoma of Unknown PrimaryLung Cancer
- First Posted Date
- 2004-05-03
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT00003943
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Johns Hopkins Oncology Center, Baltimore, Maryland, United States
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2004-05-03
- Last Posted Date
- 2010-04-02
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 280
- Registration Number
- NCT00003972
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Vaccine Therapy in Treating Women With Metastatic Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2004-05-03
- Last Posted Date
- 2013-03-26
- Lead Sponsor
- Oncothyreon Canada Inc.
- Target Recruit Count
- 950
- Registration Number
- NCT00003638
- Locations
- 🇨🇦
Biomira Inc., Edmonton, Alberta, Canada
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer
- Conditions
- Ovarian Cancer
- First Posted Date
- 2004-05-03
- Last Posted Date
- 2012-09-26
- Lead Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Target Recruit Count
- 3
- Registration Number
- NCT00005612
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2004-04-30
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 25
- Registration Number
- NCT00003397
- Locations
- 🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
Combination Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2004-04-29
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- St. Luke's Medical Center
- Registration Number
- NCT00002481
- Locations
- 🇺🇸
St. Luke's Medical Center, Milwaukee, Wisconsin, United States
Vaccine Therapy, Chemotherapy, and GM-CSF in Treating Patients With Advanced Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2004-04-29
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- St. Vincent Medical Center - Los Angeles
- Registration Number
- NCT00002773
- Locations
- 🇺🇸
St. Vincent Medical Center - Los Angeles, Los Angeles, California, United States
Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2004-04-29
- Last Posted Date
- 2013-07-24
- Lead Sponsor
- Yale University
- Target Recruit Count
- 40
- Registration Number
- NCT00002680
- Locations
- 🇺🇸
Yale Comprehensive Cancer Center, New Haven, Connecticut, United States
Combination Chemotherapy in Treating Children With Lymphoma
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2004-04-29
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 221
- Registration Number
- NCT00002590
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital of Columbus, Columbus, Ohio, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Allogeneic Transplantation Using Mini-Conditioning for Treatment of Stage IV Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2004-04-29
- Last Posted Date
- 2010-06-10
- Lead Sponsor
- Case Comprehensive Cancer Center
- Registration Number
- NCT00006261
- Locations
- 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.